Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.

Ozutsumi T, Namisaki T, Shimozato N, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Nakanishi K, Sato S, Sawada Y, Saikawa S, Kitagawa K, Takaya H, Kawaratani H, Kitade M, Moriya K, Noguchi R, Akahane T, Mitoro A, Yoshiji H.

Int J Mol Sci. 2020 Mar 21;21(6). pii: E2164. doi: 10.3390/ijms21062164.

2.

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients.

Kaji K, Saikawa S, Takaya H, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Tsuji Y, Sawada Y, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.

Antibiotics (Basel). 2020 Mar 29;9(4). pii: E145. doi: 10.3390/antibiotics9040145.

3.

Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.

Tsuji Y, Kawaratani H, Ishida K, Kaya D, Kubo T, Fujinaga Y, Sawada Y, Takaya H, Shimozato N, Kaji K, Namisaki T, Moriya K, Akahane T, Yoshiji H.

Dig Dis. 2019 Oct 25:1-6. doi: 10.1159/000504044. [Epub ahead of print]

PMID:
31655803
4.

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats.

Kaya D, Kaji K, Tsuji Y, Yamashita S, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H.

Cells. 2019 Sep 26;8(10). pii: E1153. doi: 10.3390/cells8101153.

5.

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.

Shimozato N, Namisaki T, Kaji K, Kitade M, Okura Y, Sato S, Moriya K, Seki K, Kawaratani H, Takaya H, Sawada Y, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Asada K, Kitagawa K, Tsuji Y, Kaya D, Ozutsumi T, Akahane T, Mitoro A, Yoshiji H.

Hepatol Res. 2019 Oct;49(10):1147-1161. doi: 10.1111/hepr.13385. Epub 2019 Jul 15.

PMID:
31177586
6.

Identification of clinical risk factors for histological progression of primary biliary cholangitis.

Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Ishida K, Ogawa H, Takagi H, Noguchi R, Mitoro A, Yamao J, Yoshiji H.

Hepatol Res. 2019 Sep;49(9):1015-1025. doi: 10.1111/hepr.13355. Epub 2019 Jun 14.

PMID:
31021038
7.

Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection.

Takeda K, Noguchi R, Namisaki T, Moriya K, Akahane T, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Fujinaga Y, Tsuji Y, Kubo T, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Mitoro A, Mashitani T, Okura Y, Yamao J, Yoshiji H.

Exp Ther Med. 2018 Sep;16(3):2743-2750. doi: 10.3892/etm.2018.6481. Epub 2018 Jul 19.

8.

Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis.

Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mitoro A, Yamao J, Yoshiji H.

Hepatol Res. 2019 Feb;49(2):232-238. doi: 10.1111/hepr.13249. Epub 2018 Oct 9.

PMID:
30198141
9.

Ancylostoma ceylanicum, novel etiological agent for traveler's diarrhea-report of four Japanese patients who returned from Southeast Asia and Papua New Guinea.

Yoshikawa M, Ouji Y, Hirai N, Nakamura-Uchiyama F, Yamada M, Arizono N, Akamatsu N, Yoh T, Kaya D, Nakatani T, Kikuchi E, Katanami Y, Satoh K, Maki R, Miyazato Y, Oba Y, Kasahara K, Mikasa K.

Trop Med Health. 2018 Mar 13;46:6. doi: 10.1186/s41182-018-0087-8. eCollection 2018.

10.

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.

Namisaki T, Moriya K, Kitade M, Takeda K, Kaji K, Okura Y, Shimozato N, Sato S, Nishimura N, Seki K, Kawaratani H, Takaya H, Sawada Y, Akahane T, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Noguchi R, Asada K, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Fujinaga Y, Yoshiji H.

Hepatol Commun. 2017 Sep 19;1(9):928-945. doi: 10.1002/hep4.1104. eCollection 2017 Nov.

11.

Glycogenic Hepatopathy in Type 1 Diabetes Mellitus.

Asada S, Kawaratani H, Mashitani T, Kaya D, Nishigori M, Kubo T, Sawada Y, Fujinaga Y, Kaji K, Kitade M, Namisaki T, Moriya K, Mitoro A, Yoshiji H.

Intern Med. 2018 Apr 15;57(8):1087-1092. doi: 10.2169/internalmedicine.9490-17. Epub 2017 Dec 27.

12.

Ancylostoma ceylanicum hookworm infection in Japanese traveler who presented chronic diarrhea after return from Lao People's Democratic Republic.

Kaya D, Yoshikawa M, Nakatani T, Tomo-Oka F, Fujimoto Y, Ishida K, Fujinaga Y, Aihara Y, Nagamatsu S, Matsuo E, Tokoro M, Ouji Y, Kikuchi E.

Parasitol Int. 2016 Dec;65(6 Pt A):737-740. doi: 10.1016/j.parint.2016.07.001. Epub 2016 Jul 20.

PMID:
27450724
13.

Severe toxicity of chemotherapy against advanced soft tissue sarcoma in Werner's syndrome: Ifosfamide-induced encephalopathy with central diabetes insipidus.

Tsukamoto S, Kurematsu Y, Honoki K, Kido A, Somekawa S, Kaya D, Sadamitsu T, Fukui H, Tanaka Y.

J Orthop Sci. 2016 May;21(3):403-6. doi: 10.1016/j.jos.2015.06.012. Epub 2015 Jun 30. No abstract available.

PMID:
26740452
14.

Tuberculous peritonitis during pegylated interferon plus ribavirin combination therapy in a patient with chronic hepatitis C.

Fukuba R, Kawaratani H, Kubo T, Kaya D, Aihara Y, Morioka C, Noguchi R, Mitoro A, Yoshiji H, Fukui H.

Nihon Shokakibyo Gakkai Zasshi. 2014 Dec;111(12):2337-45. Japanese.

PMID:
25482910

Supplemental Content

Loading ...
Support Center